Skip to main content
. 2024 Nov 20;29(2):67. doi: 10.3892/ol.2024.14813

Figure 2.

Figure 2.

AZD2281 upregulates FABP4 expression. (A) mRNA expression of BRCA1, BRCA2, PPARγ and FABP4 at different time points (ctrl, 12, 24 and 48 h) after treatment with 400 nM AZD2281 in OVCAR5 and COV362 cells. ***P<0.001. (B) Protein expression of BRCA1, BRCA2, PPARγ, cEBPα and FABP4 at different time points (ctrl, 12, 24 and 48 h) after treatment with 400 nM AZD2281 in OVCAR5 and COV362 cells. *P<0.05 vs. Ctrl;**P<0.01 vs. Ctrl;***P<0.001 vs. Ctrl; ****P<0.0001 vs. Ctrl. Fold enrichments of cEBPα in the (C) FABP4 and (D) PPARγ promoters at different time points (ctrl, 12, 24 and 48 h) after treatment with 400 nM AZD2281. *P<0.05 vs. Ctrl; **P<0.01 vs. Ctrl; ***P<0.001 vs. Ctrl; ***P<0.001 vs. Ctrl. FABP4, fatty acid binding protein 4; BRCA, breast cancer susceptibility gene; PPARγ, peroxisome proliferator activated receptor γ; cEBPα, CCAAT enhancer binding protein α; ChIP, chromatin immunoprecipitation; Ctrl, control.